1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Polymyositis Treatment Market
2.3. Global Polymyositis Treatment Market, By Type of Drug Class, 2025 (US$ Million)
2.4. Global Polymyositis Treatment Market, By Pipeline Analysis, 2025 (US$ Million)
2.5. Global Polymyositis Treatment Market, By Geography, 2025 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2025
3. Polymyositis Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Polymyositis Treatment Market Vendors
3.2. Strategies Adopted by Polymyositis Treatment Market Vendors
4. Polymyositis Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Polymyositis Treatment Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape
5. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Immunosuppressant
5.3.1.1. Methotrexate
5.3.1.2. Azathioprine
5.3.1.3. Cyclosporine
5.3.1.4. Tacrolimus
5.3.1.5. Mycophenolate
5.3.2. Alkylating Agent
5.3.2.1. Cyclophosphamide
5.3.2.2. Chlorambucil
5.3.3. Immunoglobulin
5.3.4. Monoclonal Antibodies
5.3.4.1. Rituximab
5.3.5. Corticosteroids
5.3.5.1. Prednisone
6. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2025 Versus 2034
6.3. Market Segmentation
6.3.1. Phase III (Sales till 2029; US$ Mn)
6.3.1.1. Ustekinumab
6.3.1.2. Abatacept
6.3.1.3. Lenabasum
6.3.1.4. Octagam 10%
6.3.1.5. Pirfenidone
6.3.2. Phase I & II (Qualitative Information)
6.3.2.1. Tocilizumab (Phase II)
6.3.2.2. PF-06823859 (Phase II)
6.3.2.3. IFN-Kinoid (Phase II)
6.3.2.4. JBT-101 (Phase II)
6.3.2.5. Tofacitinib (Phase I)
6.3.2.6. VIB7734 (Phase I)
7. North America Polymyositis Treatment Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
7.3. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
7.4. Polymyositis Treatment Market: By Region, 2024-2034, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
7.4.1.1.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
7.4.1.2.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
7.4.1.3.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
8. UK and European Union Polymyositis Treatment Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
8.3. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
8.4. Polymyositis Treatment Market: By Region, 2024-2034, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
8.4.1.1.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
8.4.1.2.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
8.4.1.3.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
8.4.1.4.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
8.4.1.5. France
8.4.1.5.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
8.4.1.5.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
8.4.1.6.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
9. Asia Pacific Polymyositis Treatment Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
9.3. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
9.4. Polymyositis Treatment Market: By Region, 2024-2034, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
9.4.1.1.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
9.4.1.2.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
9.4.1.3. India
9.4.1.3.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
9.4.1.3.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
9.4.1.4.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
9.4.1.5.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
9.4.1.6.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
10. Latin America Polymyositis Treatment Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
10.3. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
10.4. Polymyositis Treatment Market: By Region, 2024-2034, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
10.4.1.1.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
10.4.1.2.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
10.4.1.3.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
11. Middle East and Africa Polymyositis Treatment Market, 2024-2034, USD (Million)
11.1. Market Overview
11.2. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
11.3. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
11.4. Polymyositis Treatment Market: By Region, 2024-2034, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
11.4.1.1.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
11.4.1.2.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Polymyositis Treatment Market: By Type of Drug Class, 2024-2034, USD (Million)
11.4.1.3.2. Polymyositis Treatment Market: By Pipeline Analysis, 2024-2034, USD (Million)
12. Company Profile
12.1. Hospira, Inc. (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
12.2. Antares Pharma, Inc.
12.3. Medexus Pharma, Inc.
12.4. Fresenius SE & Co. KGaA
12.5. Mylan N.V.
12.6. Alcami Corporation
12.7. Teva Pharmaceutical Industries Ltd.
12.8. Novartis AG
12.9. Genentech, Inc.
12.10. Bristol-Myers Squibb
12.11. Janssen Pharmaceutical
12.12. Corbus Pharmaceuticals Inc.
12.13. Octapharma
12.14. Beijing Continent Pharmaceutical Co, Ltd.
12.15. Pfizer, Inc.
12.16. Neovacs
12.17. Viela Bio
